Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
Morihito OkadaKen KatoByoung Chul ChoMasanobu TakahashiChen-Yuan LinKeisho ChinShigenori KadowakiMyung-Ju AhnYasuo HamamotoYuichiro DokiChueh-Chuan YenYutaro KubotaSung-Bae KimChih-Hung HsuEva HoltvedIoannis XynosYasuhiro MatsumuraAkira TakazawaYuko KitagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Nivolumab as second-line therapy demonstrated clinically meaningful long-term improvement in OS compared with chemotherapy in previously treated patients with advanced ESCC. The OS was consistently improved in the nivolumab group compared with the chemotherapy group regardless of BOR. Nivolumab was well tolerated over the 3-year follow-up. See related commentary by Yoon et al., p. 3173.